Expression, Characterization and Selective Chemical Inhibition of Essential Schistosoma mansoni Tegumental Acetylcholinesterase (SmTAChE)
International Journal of Molecular Sciences · 25.02.2025 · 26 (5) · 1975
DOI: 10.3390/ijms26051975 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.02.2025. Verfasst von Patrick J Skelly und 1 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Helminthology Laboratory, Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, Nor…. Hauptthemen laut MEDLINE: Schistosoma mansoni, Acetylcholinesterase, Cholinesterase Inhibitors, Helminth Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Schistosomiasis, a parasitic disease caused by worms of the genus Schistosoma, affects >250 million people worldwide. With no available vaccine, treatment relies solely on one drug—praziquantel—underscoring the urgent need for new therapies. We identified a tegumental, non-neuronal acetylcholinesterase (AChE) from Schistosoma mansoni—SmTAChE—as a promising drug target. RNA interference confirmed its essential role in parasite survival, as gene suppression significantly reduced parasite recovery from infected animals. Here, we produced functionally active recombinant SmTAChE by using a mammalian expression system. Biochemical characterization confirmed its identity as a true acetylcholinesterase, with the highest turnover rate (Kcat = 373 ± 39 s−1) and catalytic efficiency (Kcat/Km = 1.17 × 106 M−1·S−1) for acetylthiocholine. Additionally, rSmTAChE was inhibited by classical AChE-specific inhibitors but not by a butyrylcholinesterase-specific inhibitor. To identify novel SmTAChE inhibitors, we developed a high-throughput chemical screening protocol (Z′ factor > 0.9) and screened a 1894-compound validation library. Twelve compounds reproducibly inhibited rSmTAChE by >30% at 7.5 µM, including known AChE inhibitors like physostigmine and new selective inhibitors. Notably, compound #2 preferentially inhibited rSmTAChE (IC50 = 0.74 µM) over human AChE (IC50 = 151 µM), thus providing a foundation for developing parasite-specific therapies targeting SmTAChE and potentially leading to new treatments for schistosomiasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Helminthology Laboratory, Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA 01536, USA.
ORCID-Profile: Akram A Da'dara
Förderung
- NIAID NIH HHS
- National Institutes of Health, National Institute of Allergy and Infectious Diseases
Zitieren
APA
Skelly, P. J., & Da'dara, A. A. (2025). Expression, Characterization and Selective Chemical Inhibition of Essential Schistosoma mansoni Tegumental Acetylcholinesterase (SmTAChE). International Journal of Molecular Sciences, 26(5), 1975. https://doi.org/10.3390/ijms26051975
Vancouver
Skelly PJ, Da'dara AA. Expression, Characterization and Selective Chemical Inhibition of Essential Schistosoma mansoni Tegumental Acetylcholinesterase (SmTAChE). International Journal of Molecular Sciences. 2025;26(5):1975. doi:10.3390/ijms26051975
BibTeX
@article{Skelly2025,
author = {Skelly, Patrick J and Da'dara, Akram A},
title = {Expression, Characterization and Selective Chemical Inhibition of Essential Schistosoma mansoni Tegumental Acetylcholinesterase (SmTAChE)},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {5},
pages = {1975},
doi = {10.3390/ijms26051975}
}
EUVIMED